<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03294980</url>
  </required_header>
  <id_info>
    <org_study_id>OFICE</org_study_id>
    <nct_id>NCT03294980</nct_id>
  </id_info>
  <brief_title>Chronic Lymphoid Leukaemia Observatory in Finistere Area, France</brief_title>
  <acronym>OFICE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <brief_summary>
    <textblock>
      Brief Summary: The purpose of the OFICE registry is to characterize and describe the CLL
      patients' population from the Finistere area and evaluates the association between different
      patient characteristics, prognosis and treatment patterns.

      Detailed Description: OFICE is a single center, prospective, observational registry of CLL
      patients designed to provide a general description of the CLL patients' population from the
      Finistere area, France. The registry will also provide information on the association of
      cytogenetic and immunophenotypic characteristics with disease progression, as well as
      treatment patterns and healthcare resource utilization. These data will be accessible and
      beneficial for researchers and physicians and will help guide clinical practice and future
      clinical or fundamental studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence</measure>
    <time_frame>Year 0 (Y)</time_frame>
    <description>Clinical data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence</measure>
    <time_frame>Year 0</time_frame>
    <description>Clinical and biological data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of baseline clinical-biological</measure>
    <time_frame>Year 0, Year 1, Year 2, Year 3</time_frame>
    <description>Clinical data, complete blood count, Matutes score and parameters, cytogenetic, IgVH mutations, CD38 (%), medical treatment will be collected</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Chronic Lymphoid Leukaemia</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cell pellet More than 95% CD5+CD19+ lymphocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Chronic Lymphoid Leukaemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of at least 18 years

          -  Clinical diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek 2008)

          -  Willing and able to provide informed consent

          -  Willing and able to provide blood sample at time of enrollment

        Exclusion Criteria:

          -  Diagnosis of other B-cell malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Reanudineau</last_name>
    <role>Study Director</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves Renaudineau</last_name>
    <email>yves.renaudineau@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Renaudineau</last_name>
      <email>Yves.renaudineau@chu-brest.fr</email>
    </contact>
    <contact_backup>
      <last_name>Adrian Tempescul</last_name>
      <email>adrian.tempescul@chu-brest.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2017</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

